|
|
|
|
| LEADER |
02754nam a2200361 u 4500 |
| 001 |
EB002001799 |
| 003 |
EBX01000000000000001164700 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 100 |
1 |
|
|a Guise, Jeanne-Marie
|
| 245 |
0 |
0 |
|a Future research needs to reduce the risk of primary breast cancer in women
|h Elektronische Ressource
|b identification of future research needs from Comparative effectiveness review no. 17
|c prepared for Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services ; prepared by Oregon Evidence-based Practice Center ; investigators, Jeanne-Marie Guise ... [et al.]
|
| 260 |
|
|
|a Rockville, MD
|b Agency for Healthcare Research and Quality
|c 2010, [2010]
|
| 300 |
|
|
|a 1 PDF file (1 v. (various pagings))
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Pilot Projects
|
| 653 |
|
|
|a United States
|
| 653 |
|
|
|a Breast Neoplasms / drug therapy
|
| 653 |
|
|
|a Research Design
|
| 653 |
|
|
|a Feasibility Studies
|
| 653 |
|
|
|a Evidence-Based Medicine
|
| 653 |
|
|
|a Breast Neoplasms / prevention & control
|
| 710 |
2 |
|
|a Effective Health Care Program (U.S.)
|
| 710 |
2 |
|
|a United States
|b Agency for Healthcare Research and Quality
|
| 710 |
2 |
|
|a Oregon Health & Science University
|b Evidence-based Practice Center
|
| 740 |
0 |
2 |
|a Comparative effectiveness of medications to reduce risk of primary breast cancer in women
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a Future research needs paper
|
| 500 |
|
|
|a Title from PDF t.p. - "September 2010.". - Mode of access: Internet
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK51261
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a The 2009 comparative effectiveness review (CER) on the effectiveness of medications to reduce the risk of primary breast cancer in women without preexisting cancer demonstrated the efficacy of two SERMs, tamoxifen citrate (RR, 0.70; 95% CI, 0.59 to 0.82; 4 trials) and raloxifene (RR, 0.44; CI, 0.27 to 0.71; 2 trials). However, the CER also outlined many adverse effects and unknowns about the medications. The objective of this pilot project was to engage stakeholders to develop and prioritize a list of research questions to address the research gaps related to the CER. First, the goal was to provide sufficient detail--including population, intervention, comparator, and outcome (PICO)--for researchers and funders to use in the development of research proposals and solicitations, respectively. Second, this project was intended to identify a feasible and effective approach to identify and prioritize future research from systematic reviews in general
|